{
    "nctId": "NCT00833963",
    "briefTitle": "A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine",
    "officialTitle": "An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Pregnancy",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Number of Participants Developing Oligohydramnios",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pregnant; women identified at any trimester of pregnancy may enroll in this study as long as enrollment occurs prior to experiencing pregnancy outcome (that is \\[i.e.\\], live birth, stillbirth, or abortion)\n* Exposure to at least one dose of trastuzumab (as adjuvant or metastatic treatment), pertuzumab plus trastuzumab combination treatment, or ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception\n* United States resident\n\nExclusion Criteria:\n\n* Prior knowledge of pregnancy outcome (i.e., live birth, stillbirth, or abortion) at time of enrollment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}